Prana receives Michael 3. Fox Foundation Grant

摘要

Prana Biotechnology Limited has received a grant from The Michael 3. Fox Foundation to support the initiation of preclinical studies that precede human trials of a novel treatment for Parkinson's disease known as PBT434. The funding was awarded after a highly competitive, international, peer-reviewed process. The support comes from the foundation's 2011 Pipeline Program to support its Therapeutic Development Initiative.'It is our hope that PBT434 will provide treatment from very early diagnosis to prevent the damage to the part of brain responsible for normal movement, thus preventing the loss of physical coordination and control experienced by Parkinson's disease patients' said Geoffrey Kempler, Prana's Executive Chairman.